Drew Blasco, Ph.D. is an Assistant Professor in the Department of Social and Behavioral Health in the School of Public Health. Dr. Blasco’s recent work seeks to better understand the implications of APOE genetic testing in the context of emerging Alzheimer’s disease treatments among providers and aging adults who may be eligible for such treatments in the near future. Dr. Blasco completed her PhD in Public Health at New York University in the Department of Social and Behavioral Sciences in 2021. Her scholarship during her PhD centered around two areas: 1) stigma related to identifying individuals as at clinical high-risk for psychosis (CHR-p); 2) the implications of future genetic testing for psychosis. Following her PhD, she completed a T32 postdoctoral fellowship at University of Michigan (2021-2023) focused on the ethical, legal, and social implications (ELSI) of genetics/genomics which was funded by the National Human Genome Research Institute (NHGRI). During her time there, she continued her research examining the psychosocial, stigma, and ethical implications of genetic testing for neuropsychiatric illnesses including serious mental illness (e.g., psychotic disorders and those identified as at-high risk for such disorders) and Alzheimer’s disease.